The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden. Tinajero J, Nguyen K, Ngo D, Agrawal V, et al. Am J Hematol 2025;100:2209-2219.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tinajero J, Nguyen K, Ngo D, Agrawal V, et al. The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden. Am J Hematol 2025;100:2209-2219.
PMID: 40926515